Patents
Literature
3 results about "Synapsis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Synapsis (also called syndesis) is the pairing of two homologous chromosomes that occurs during meiosis. It allows matching-up of homologous pairs prior to their segregation, and possible chromosomal crossover between them. Synapsis takes place during prophase I of meiosis. When homologous chromosomes synapse, their ends are first attached to the nuclear envelope. These end-membrane complexes then migrate, assisted by the extranuclear cytoskeleton, until matching ends have been paired. Then the intervening regions of the chromosome are brought together, and may be connected by a protein-RNA complex called the synaptonemal complex. Autosomes undergo synapsis during meiosis, and are held together by a protein complex along the whole length of the chromosomes called the synaptonemal complex. Sex chromosomes also undergo synapsis; however, the synaptonemal protein complex that holds the homologous chromosomes together is only present at one end of each sex chromosome.
Engineered extracellular vesicles comprising fusion proteins
Described herein are compositions and techniques related to generation and therapeutic application of artificial synapses. Artificial synapses are engineered extracellular vesicles, including exosomes, which incorporate sticky binders on their surface to anchor signaling domains against biological targets, such as receptors. These engineered additives can be organized in genetic vector constructs, expressed in mammalian cells, wherein the sticky binders attach to extracellular vesicles such as exosomes, thereby presenting their joined signaling domains which are rapidly taken up by recipient cells. Artificial synapses adopt the hallmark biophysical and biochemical features of extracellular vesicles, allowing for rapid deployment and scale-up. Importantly, this strategy can allow for kinetically favorable signal generation and signal propagation. This includes, for example, increasing density of agonist presentation to support receptor clustering—an onerous barrier for traditional receptor targeting strategies.
Owner:DIADEM BIOTHERAPEUTICS INC
Application of substance taking ANGPTL4 or coding gene thereof as target spot in preparation of product for treating cerebellar ataxia
The invention discloses application of a substance taking ANGPTL4 protein or a coding gene thereof as a target spot in preparation of a product for treating cerebellar ataxia. The invention belongs to the technical field of biology, and particularly relates to application of a substance taking ANGPTL4 or a coding gene thereof as a target spot in preparation of a product for treating cerebellar ataxia. The invention provides an application of a substance for reducing ANGPTL4 gene expression, a substance for reducing ANGPTL4 protein activity or a substance for reducing ANGPTL4 protein content in preparation of a product for treating or / and preventing or / and delaying cerebellar ataxia and an application of a product for reducing formation of inhibitory synapses.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES
Novel synapse targeting signal peptides and uses thereof
Provided herein are novel signal peptides that direct encoded proteins to synapses, recombinant polypeptides comprising the signal peptides, nucleic acid molecules encoding the recombinant polypeptides, pharmaceutical compositions comprising the nucleic acid molecules, and methods of use thereof.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST